Aldeyra Therapeutics, Inc. — Form 8-K Summary
Event date: September 29, 2026. This is an event-driven filing, not a quarterly or annual financial report.
Business context and regulatory update
Aldeyra reported that it intends to submit a Formal Dispute Resolution Request (FDRR) to the FDA’s Office of New Drugs, appealing the March 16, 2026 Complete Response Letter that denied approval of its new drug application for reproxalap to treat dry eye disease. The company held a Type D meeting with the FDA on September 25, 2026. It expects to submit the FDRR and meet with the Office of New Drugs in the fourth quarter of 2026.
Financial position and key metrics
- Aldeyra announced that its projected operational cash runway has been extended into 2029.
- The filing does not provide a clear cash balance, the amount or source of the runway extension, revenue, profit or loss, cash-flow figures, margins, debt, or other liquidity metrics.
Material changes, outlook, and risks
The stated cash-runway projection extends into 2029; the filing does not quantify the change from the prior projection. The FDRR, subsequent FDA discussions, any potential NDA resubmission, and potential approval of reproxalap remain forward-looking and uncertain. The filing identifies risks discussed in Aldeyra’s 2025 Form 10-K and its Form 10-Q for the quarter ended June 30, 2026, among other factors.
Important facts for investors to verify
- Whether and when Aldeyra submits the FDRR and meets with the FDA in the fourth quarter of 2026.
- The FDA’s response to the dispute and any resulting requirements or timeline for a potential NDA resubmission.
- The assumptions behind the projected cash runway into 2029 and the company’s cash position and spending in subsequent financial filings.
- The accompanying September 29, 2026 presentation and press release, which are listed as exhibits but are not included in the supplied filing text.